EuroQuity Blog

Join the InvestHorizon e-pitch Session on October the 15th at 5:00pm

The next InvestHorizon pitch session will be held online on October 15th, at 5PM CEST. Six European start-up are looking for funding.

Our next InvestHorizon pitch session will be held online on October 15th at 5:00 PM CEST.
7 companies will be presented.
All these Serie A companies are part of the European InvestHorizon acceleration program, and are looking for funds to continue their growth.

Here is the list of  the 7 deeptech companies:


Biotech – Diagnostic Tests
Innovative platform aimed at eliminating cancer misdiagnosis and becoming the worldwide standard. Our cross-validation approach creates a precise, 98% accurate cancer profile for each patient, allowing oncologists to suggest specific, personalized cancer treatments better able to save patients' lives. Winner of StartUp Awards 2016, 2017 “New Europe 100” Challengers, JCI Creative Young Entrepreneur 2018, Biotech Standard of Excellence WebAward 2018, Health Hub Vienna accelerator 2018, CESAwards 2018, Seal of Excellence holder, Member of Oslo Cancer Cluster | €4.5 M sought - Slovakia

Healthcare / Sleep Diagnostics
A better way to screen and diagnose sleep apnea patients - an under-served market of almost 800 million people globally. The company has developed a solution which is easy-to-use and comfortable for the patient and scalable and cost-efficient for the health care sector. Winner of "best of Slush" award 2018. Awarded a grant of 1,75 M€ by Horizon2020 program. | 2M€ sought – Finland

Digital Health – Data Brooker
The company collects and processes pharmacies commercial data to build up a panel. It’s a data broker as SAAS provider for pharmacies, pharmacy chains, pharmaceutical labs. The data is accessed for their customers through APIs & self-service apps. They only collect commercial data, excluding any « personal » data. Data are extracted hourly from the pharmacy ERP and are only extracted through an explicit agreement and contract with the pharmacy owner. In these General Conditions, the pharmacy owner concedes the right to collect, process and commercialize the data. They have already deployed the solution on 5,000 point of sales with a steady growth of the panel. | €2.5 M sought - France
The company is actively involved in the fields of physical rehabilitation and sports biomechanics producing precise measuring and training devices for assessment/exercising and follow-up of patients and athletes.
The product is the first centralized solution for functional evaluation and monitoring. It consists of an application and 5 devices to cover almost all the functional work in rehabilitation.
 €360 K turnover; +700 Users | €1.3 M sought - France
Biotech – Transthyretin amyloidosis
A biotech company focused on the design of organ-targeted, high-quality drug candidates for the treatment of life-threatening transthyretin-mediated amyloidosis (ATTR). They work closely with patients and physicians to understand and answer to multiple clinical manifestations of these pathologies which represent unmet medical needs.
The company has succeeded in designing novel and potent TTR stabilizes endowed with physicochemical and pharmacological requirements for the development of two innovative products | €2.5 M sought - Portugal
The company seeks, develops and qualifies innovative biomarkers for the development of diagnostics in the field of neurological diseases. The purpose of the company is to translate new diagnosis methods for various neurodegenerative diseases into products, and to promote the use of these tests in clinical practice. Their know-how is based on the detection of blood biomarkers.
Currently their biomarker R&D program is dedicated to the clinical qualification of new biomarkers and diagnostic tools for the diagnosis and the follow-up of the Alzheimer’s disease | €2.5 M sought - France

le Monday, October 7th 2019
Stay informed by suscribing to our newsletter